Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial

CONCLUSIONS: In this phase 1b clinical trial, the MTD of gemcitabine/nab-paclitaxel (1000 mg/m² / 125 mg/m²) and afatinib (30 mg) was established. In a cohort of 11 patients, the combination showed an acceptable safety …